[go: nahoru, domu]

MX2018014610A - Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment. - Google Patents

Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment.

Info

Publication number
MX2018014610A
MX2018014610A MX2018014610A MX2018014610A MX2018014610A MX 2018014610 A MX2018014610 A MX 2018014610A MX 2018014610 A MX2018014610 A MX 2018014610A MX 2018014610 A MX2018014610 A MX 2018014610A MX 2018014610 A MX2018014610 A MX 2018014610A
Authority
MX
Mexico
Prior art keywords
antibody
combination
lymphoma
lymphoma treatment
hodgkin
Prior art date
Application number
MX2018014610A
Other languages
Spanish (es)
Inventor
FARSACI Benedetto
Josephson Neil
CAO Anthony
Heiser Ryan
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2018014610A publication Critical patent/MX2018014610A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The application provides to methods for treating Hodgkin lymphoma or non Hodgkin lymphoma in a subject comprising - nivolumab, or pembrolizumab, two PD-1-blocking antibodies that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma in combination with - an anti CD30 antibody, such as brentuximab vedotin.
MX2018014610A 2016-06-02 2017-06-01 Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment. MX2018014610A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344866P 2016-06-02 2016-06-02
US201662382839P 2016-09-02 2016-09-02
PCT/US2017/035521 WO2017210473A1 (en) 2016-06-02 2017-06-01 Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment

Publications (1)

Publication Number Publication Date
MX2018014610A true MX2018014610A (en) 2019-02-28

Family

ID=59067913

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018014610A MX2018014610A (en) 2016-06-02 2017-06-01 Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment.
MX2022003571A MX2022003571A (en) 2016-06-02 2018-11-27 Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003571A MX2022003571A (en) 2016-06-02 2018-11-27 Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment.

Country Status (19)

Country Link
US (2) US11299543B2 (en)
EP (2) EP4248989A3 (en)
JP (3) JP2019517505A (en)
KR (3) KR20240145059A (en)
CN (1) CN109476752A (en)
AU (1) AU2017274444B2 (en)
BR (1) BR112018074619A2 (en)
CA (1) CA3026246A1 (en)
DK (1) DK3464368T3 (en)
ES (1) ES2951650T3 (en)
FI (1) FI3464368T3 (en)
HU (1) HUE063911T2 (en)
IL (1) IL263165A (en)
MX (2) MX2018014610A (en)
PL (1) PL3464368T3 (en)
PT (1) PT3464368T (en)
SG (2) SG10202101062YA (en)
SI (1) SI3464368T1 (en)
WO (1) WO2017210473A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
FI3464368T3 (en) 2016-06-02 2023-09-12 Bristol Myers Squibb Co Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
MA50369A (en) * 2017-10-13 2020-08-19 Seattle Genetics Inc MODULATION OF THE IMMUNE RESPONSE USING ANTIBODY-DRUG CONJUGATES
MX2020006171A (en) * 2018-01-12 2020-09-03 Bristol Myers Squibb Co Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer.
EP3814379A4 (en) * 2018-05-07 2022-03-30 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
EP3902838A4 (en) * 2018-12-26 2022-12-21 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
MX2022003357A (en) 2019-09-25 2022-05-03 Seagen Inc Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers.
WO2021119105A1 (en) 2019-12-09 2021-06-17 Seagen Inc. Combination therapy with liv1-adc and pd-1 antagonist
CN111407894B (en) * 2020-02-21 2022-04-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Novel combined targeted drug for treating relapsed/refractory T cell lymphoma
EP4149559A1 (en) * 2020-05-13 2023-03-22 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
CN116964098A (en) 2021-03-01 2023-10-27 南特生物公司 anti-CD 30 monoclonal antibodies and chimeric antigen receptors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360254A1 (en) * 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
JP4409430B2 (en) 2002-07-03 2010-02-03 小野薬品工業株式会社 Immunostimulatory composition
CN101899114A (en) 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
CN117534755A (en) 2005-05-09 2024-02-09 小野药品工业株式会社 Human monoclonal antibodies to programmed death-1 (PD-1) and methods of treating cancer using anti-PD-1 antibodies
KR101888321B1 (en) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
BRPI0713000A8 (en) * 2006-06-12 2017-12-05 Trubion Pharmaceuticals Inc SINGLE CHAIN MULTIESPECIFIC BINDING PROTEIN, PHARMACEUTICAL COMPOSITION AND USE OF SAID SINGLE CHAIN MULTIESPECIFIC BINDING PROTEIN
CL2007003622A1 (en) * 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA023148B1 (en) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Compositions of pd-1 antagonists and use thereof
CN102245640B (en) 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 Anti-PD-L1 antibodies and their use to enhance T-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
MX359551B (en) 2009-11-24 2018-10-02 Medimmune Ltd Targeted binding agents against b7-h1.
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
PT2785375T (en) 2011-11-28 2020-10-29 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014124227A1 (en) * 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
ES2878749T3 (en) * 2013-02-20 2021-11-19 Innate Pharma A compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T-cell lymphoma
JP6742903B2 (en) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド Antibodies to programmed death-1 (PD-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SI3702373T1 (en) 2013-09-13 2022-11-30 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
US20160303231A1 (en) * 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
EA035037B1 (en) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
CN114702586A (en) 2015-03-13 2022-07-05 西托姆克斯治疗公司 anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof
FI3464368T3 (en) 2016-06-02 2023-09-12 Bristol Myers Squibb Co Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
EP3463457B1 (en) 2016-06-02 2023-06-28 Bristol-Myers Squibb Company Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Also Published As

Publication number Publication date
ES2951650T3 (en) 2023-10-24
JP2024020202A (en) 2024-02-14
KR20240145059A (en) 2024-10-04
KR102710067B1 (en) 2024-09-26
BR112018074619A2 (en) 2019-03-06
CN109476752A (en) 2019-03-15
MX2022003571A (en) 2022-04-25
AU2017274444B2 (en) 2024-08-01
US20190218293A1 (en) 2019-07-18
EP4248989A2 (en) 2023-09-27
EP3464368B1 (en) 2023-06-28
AU2017274444A1 (en) 2018-12-13
SG11201810454YA (en) 2018-12-28
KR20190008962A (en) 2019-01-25
HUE063911T2 (en) 2024-02-28
WO2017210473A1 (en) 2017-12-07
SI3464368T1 (en) 2023-10-30
SG10202101062YA (en) 2021-03-30
PL3464368T3 (en) 2023-08-28
KR20230119265A (en) 2023-08-16
US11299543B2 (en) 2022-04-12
JP2019517505A (en) 2019-06-24
EP3464368A1 (en) 2019-04-10
EP4248989A3 (en) 2023-12-27
FI3464368T3 (en) 2023-09-12
US20220298243A1 (en) 2022-09-22
PT3464368T (en) 2023-08-17
IL263165A (en) 2018-12-31
JP2022176973A (en) 2022-11-30
CA3026246A1 (en) 2017-12-07
DK3464368T3 (en) 2023-10-02

Similar Documents

Publication Publication Date Title
MX2022003571A (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment.
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
MX2021012134A (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38.
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
NZ739750A (en) Anti-tigit antibodies and methods of use
MA39906A (en) Combination therapies for the treatment of cancer
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2018010672A (en) Antibodies to cd40 with enhanced agonist activity.
EA036102B9 (en) Glycotargeting therapeutics
MX2020006534A (en) Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule.
SG10201809411PA (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
AU2016282877A8 (en) Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2019001958A (en) Methods of treating crohn's disease with an anti-nkg2d antibody.
BR112022001690A2 (en) Treatment of evasive immune tumors
MX2017013047A (en) Treatment of pain.
MX2018009499A (en) Egfl6 specific monoclonal antibodies and methods of their use.
WO2017181099A8 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
MX2019001337A (en) Methods of treating and preventing cancer treatment side effects.
MX2021010313A (en) Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies.
MY194488A (en) Syd985 treatment of t-dm1 refractory cancer patients
MX2020011377A (en) Methods and compositions for treating chronic urticaria.
PH12019500344A1 (en) Immunotherapy for polyomaviruses
MX2019014090A (en) Methods for the treatment of chronic pouchitis.